Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07406360 · ClinicalTrials.gov registry record · Phase 3
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
A Phase 3 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,209
- Enrollment target
NCT07406360 is a Phase 3 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 1,209 participants.
The verdict
NCT07406360, a Phase 3 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,209 participants
- Enrollment target
Study Summary
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administered as a second dose in children 15 months to 6 years of age who were previously primed with a first dose of any combination of measles, mumps, rubella and varicella-containing vaccine(s).
Interventions
- BIOLOGICAL MMRVNS
- BIOLOGICAL MMRV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,209 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2028-07-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07406360
The ClinicalTrials.gov registry entry for NCT07406360 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MMRVNS is the first listed.
NCT07406360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07406360 about?
NCT07406360 is a clinical study titled "A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age". This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella) vaccine (ProQuad) that is already licensed for this route, when administer...
What is the current status of trial NCT07406360?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,209 participants. The study started on 2026-05-11. Estimated completion is 2028-07-20.
What interventions are being tested in trial NCT07406360?
The interventions under investigation include: MMRVNS (BIOLOGICAL), MMRV (BIOLOGICAL).
Who is sponsoring clinical trial NCT07406360?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.